Advertisement

Rauschdrogen pp 555-789 | Cite as

Stimulantia

  • Thomas Geschwinde
Chapter

Zusammenfassung

Vorbemerkung: Die Zusammenfassung verschiedener Wirkstoffe unter diesem, von lat. stimulus (Stachel, Antrieb, Reiz) abgeleiteten Begriff stellt auf die charakteristische anregende und leistungssteigernde Wirkungskomponente dieser Gruppe von Rauschdrogen ab (engl. CNS Stimulants). Synonym wird der ältere, von Lewin geprägte, heute weniger gebräuchliche Begriff „Excitantia“ verwandt.

Literatur

  1. Al-Hebshi NN, Skaug N (2005) Khat (Catha edulis): an updated review. Addic Biol 10:299–307CrossRefGoogle Scholar
  2. Amin M et al (1990) Acute myocardial infarction and chest pain syndrome after cocaine use. Am J Cardiol 66:1434–1437CrossRefGoogle Scholar
  3. Andrews P (1997) Cocaethylene toxicity. J Addict Dis 16:75–84CrossRefGoogle Scholar
  4. Angrist B, Corwin J, Bartlik B, Cooper T (1987) Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry 22:1357–1368CrossRefGoogle Scholar
  5. Archer R (2009) Fluoromethcathinone: A new substance of abuse. Foren Sci Intern 185(1):10–20CrossRefGoogle Scholar
  6. Asghar K, De Souza E (Hrsg) (1989) Pharmacology and toxicology of amphetamine and related designer drugs. NIDA Res Monogr 94Google Scholar
  7. Axt KJ, Molliver ME (1991) Immunocytochemical evidence for methamphetamine-induced serotonergic exon loss in the rat brain. Synapse 9:302–313CrossRefGoogle Scholar
  8. Bachmann P (1976) Das hyperkinetische Syndrom im Kindesalter. Huber, BernGoogle Scholar
  9. Baumgartner WA, Black CT, Jones PF, Blahd WH (1982) Radioimmunassay of cocaine in hair, concise communication. J Nucl Med 23:790–792Google Scholar
  10. Bailey DN (1996) Cocaine and cocaethylene binding to human tissues: A preliminary study. Ther Drug Monit 18:280–283CrossRefGoogle Scholar
  11. Beck NE, Hale JE (1993) Cocaine „body-packers“. Brit J Surg 80:1513–1516CrossRefGoogle Scholar
  12. Beck O, Kraft M, Moeller M, Smith BL et al (2000) Frontline immunochromatographic device for on-site urine testing of amphetamines: laboratory validation using authentic specimens.Am Clin Biochem 37(Ptz):199–204CrossRefGoogle Scholar
  13. Beil H, Trojan A (1974) Zur Problematik des Amphetaminil (AN 1)-Missbrauchs. MMW 116(48):2121–2123Google Scholar
  14. Bejerot N (1970) A comparison of the effects of cocaine and synthetic central stimulants. Br J Addict 65:35–37CrossRefGoogle Scholar
  15. Bejhadj-Tahar H, Sadeg N (2005) Methcathinone: a new postindustrial drog. Forensic Sci Intern 153:99–101CrossRefGoogle Scholar
  16. Belal T, Awad T, De Ruiter J, Clark CR (2009) GC-IRD methods fort he identification of isomeric ethoxyphenethylamines and methoxymethcathinones. For Sci Intern 184:54–63Google Scholar
  17. Bell DS (1965) Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 111: 701–707CrossRefGoogle Scholar
  18. Bell DS (1973) The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 29:34–40CrossRefGoogle Scholar
  19. Benchimol A, Bartrail H, Dresser KB (1978) Accelerated ventricular rhythm and cocaine abuse. Ann Intern Med 88:519–521CrossRefGoogle Scholar
  20. Bettinger J (1980) Cocain intoxication, massive oral overdose. Ann Emerg Med 10:429–433CrossRefGoogle Scholar
  21. Birkholz M, Kropp S, Bleich S et al (1997) Exkorporation von Betäubungsmitteln. Kriminalistik 4:277–283Google Scholar
  22. Birnbach DJ, Stein DJ, Thomas K (1993) Instant recognition of the cocaine abusing parturient. Anesthesiol 79:A987Google Scholar
  23. Blejer-Prieto H (1965) Coca leaf and cocaine addiction – some historical notes. Can Med Assoc J 93:700–704Google Scholar
  24. Bogusz MJ, Schmidt G (1991) Cocain-Missbrauch – Neue Bedrohung mit der alten Substanz. Zbl Rechtsmed 35:783–793Google Scholar
  25. Bogusz MJ,Althoff H, Erkens M et al (1995) Internally concealed cocaine: analytical and diagnostic aspects. J Forensic Sci 40:811–815CrossRefGoogle Scholar
  26. Bogusz MJ, Kala M, Maier RD (1997) Determination of phenylisothiocyanate derivates of amphetamine and its analogues in biological fluids by HPLC-APCI-MS or DAD. J Anal Toxicol 21:59–69CrossRefGoogle Scholar
  27. Bossong MG, Van Dijk JP, Niesink RJ (2005) Methylone and mCPP: Two new drugs af abuse?. Addic Biol 10(4):321–323CrossRefGoogle Scholar
  28. Brennneisen R, Fisch HU, Koelbing U et al (1990) Amphetamine-like effects in humans of the khat alkaloid cathinone. Brit J Clin Pharmacol 30(6):825–828CrossRefGoogle Scholar
  29. Briellmann TA, Dussy FE, Schwerzmann T, Dittmann V (2001) Cocain und Heroin auf Banknoten. Kriminalistik 2:113–116Google Scholar
  30. Bruns O (1941) Pervitin – Pharmakologie und Klinik. Fortschr Ther 17: 37–44, 90–100Google Scholar
  31. Brzezinski MR, Spink BJ, Dean RA et al (1997) Human liver carboxylesterase hCE-1: binding specifity for cocaine, heroin, and their metabolites and analogs. Drug Metab Dispos 25: 1089–1096Google Scholar
  32. Bühring P (2013) Drogenmissbrauch: immer mehr Abhängige von “Crystal Meth”. Dtsch Ärztebl 110: A 912Google Scholar
  33. Bundeskriminalamt (Hrsg) (1981) Kokain-Informationsschrift.WiesbadenGoogle Scholar
  34. Bunn WH, Giannini AJ (1992) Cardiovascular complications of cocaine abuse.Am Fam Physician 45:769–773Google Scholar
  35. Buschmann CT, Foißner C, Schmidt S et al (2009) Letale Kokainintoxikation eines Bodypackers. Kriminalistik 8(9):480–481Google Scholar
  36. Caldwell J et al (1974) The biochemical pharmacology of drug abuse. I. Amphetamine, cocaine and LSD. Clin Pharmacol Ther 16:625–633CrossRefGoogle Scholar
  37. Chambers CD, Taylor WJR, Moffett AD (1972) The incidence of cocaine abuse among methadone maintenance patients. Int J Addict 7:427–441CrossRefGoogle Scholar
  38. Cleckner PJ (1976) Blowing some lines: Intracultural variation among Miami cocaine users. J Psychedelic Drugs 8:37–42CrossRefGoogle Scholar
  39. Cohen H (1972) The amphetamine manifesto. Olympia Press, New YorkGoogle Scholar
  40. Cohen SV (1976) Influence of cocaine on sexuality. Med Aspects Hum Sex 10:149–152Google Scholar
  41. Colpaert FC et al (1978) Neuroleptic interference with the cocaine cue: Internal stimulus control of behavior and psychosis. Psychopharmacol (Berlin) 58:257CrossRefGoogle Scholar
  42. Cone EJ (1995) Pharmacokinetics and pharmacodynamic of cocaine. J Anal Toxicol 19:459–478CrossRefGoogle Scholar
  43. Cone EJ,Weddington WW(1989) Prolonged occurence of cocaine in human saliva and urine after chronic abuse. J Anal Toxicol 13:65–68CrossRefGoogle Scholar
  44. Cone EJ, Oyler J, Darwin WD(1997) Cocaine disposition in saliva following intravenous, intranasal and smoked administration. J Anal Toxicol 21:465–475CrossRefGoogle Scholar
  45. Connell PH (1958) Amphetamine psychosis. Chapman & Hall, LondonGoogle Scholar
  46. Cook CE (1990) Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine and methamphetamine. NIDA Res Monogr 99:6–23Google Scholar
  47. Cooper H, Ellinwood EH (1981) Cocain und Cocainismus. Dtsch Ärztebl 19:173–179Google Scholar
  48. Cox G, Rampes H (2003) Adverse effects of khat: a review. Advan Psychiatr Treatm 9:456–463CrossRefGoogle Scholar
  49. Cozzi NV, Shulgin AT, Jacob III P, Ruoho AE (1998) Methcathinone and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (Methylone) selectivity inhibt plasma membrane catecholamine reuptake transporters. Soc Neurosci Abstr 25:381–388Google Scholar
  50. Cozzi NV, Shulgin AT, Ruoho AE (1998) Methcathinone (MCAT) and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (MDMCAT) inhibit (3H) serotonin uptake into human platelets. Am Chem Soc Div of Med Abstr 215:152Google Scholar
  51. Cozzi NV, Sievert MK, Shulgin AT, Jacob III P, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Europ J Pharmakol 381:63–69CrossRefGoogle Scholar
  52. Cregler LL, Mark H (1986) Special report: Medical complications of cocaine abuse. N Engl J Med 315:1495–1500CrossRefGoogle Scholar
  53. Crowley A (1973) Cocaine. Level, San FranciscoGoogle Scholar
  54. Dal Cason IA (1997) The characterization of some 3,4-methylenedioxycathinone (MDCATH) homologes. For Sci Intern 87:9–53Google Scholar
  55. Daras M, Tuchmann AJ, Koppel BS et al (1994) Neurovascular complications of cocaine. Acta Neurol Scand 90:124–129CrossRefGoogle Scholar
  56. Dargan PI, Albert S, Wood DM (2010) Mephedrone use and associated adverse effects in school and college/university students before the UK legalislation change. Oxford J of Med 103(10):875–879Google Scholar
  57. Darke S, Hall W (1995) Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend 39:231–235CrossRefGoogle Scholar
  58. Daube H (1942) Pervitinpsychosen. Nervenarzt 15:20–25Google Scholar
  59. Decorte T (2000) The taming of cocaine. VUB University press, BrusselGoogle Scholar
  60. De Letter EA, Coopman VA, Cordonnier JA, Piette MH (2001) One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinic-pathological findings. Intern J of LegAL Medicine 114:352–356CrossRefGoogle Scholar
  61. Dhaifalah I, Santavy J (2004) Khat habit and its health effect. A natural amphetamine. Biomedical Papers 148(1):11–15CrossRefGoogle Scholar
  62. Dickson AJ, Vorce SP, Levine B, Past MR (2010) Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 34(3):162–168CrossRefGoogle Scholar
  63. Van Dyke C, Jatlow P, Ungerer J, Barash PG (1978) Oral cocaine: Plasma concentrations and central effects. Science 200:211–213CrossRefGoogle Scholar
  64. Van Dyke C et al (1979) Cocaine and lidocaine have similar psychological effects after intranasal application. Life Sci 24:271–274Google Scholar
  65. Ellinwood EH Jr, Kilbey MM (Hrsg) (1977) Cocaine and other stimulants. Plenum, New YorkGoogle Scholar
  66. Elliot SP (2000) Fatal poisoning with a new phenethylamine: 4-methylthioamphetamine (4-MTA). J Analyt Toxicol 24:85–89CrossRefGoogle Scholar
  67. EMCDD (2002) Report on the risk assessement of ketamine in the framework of the joint action on new synthetixc drugs. BelgiumGoogle Scholar
  68. EMCDD (2009) Understanding the “Spice” phenomenon. EMCDDA Thematic Paper, LisbonGoogle Scholar
  69. EMCDD (2011) Synthetic cocaine derivates. Eur Monitoring Centre Drugs Drug AddictGoogle Scholar
  70. EMCDD (2011) Synthetic cathinones. Eur Monitoring Centre Drugs Drig AddictGoogle Scholar
  71. Epstein PN et al (1978) Changes in effects of cocaine during chronic treatment. Res Commun Chem Pathol Pharmacol 22:93–105Google Scholar
  72. Erhardt E (1993) Wie gefährlich ist Kokain? Kriminalistik 7:447–452Google Scholar
  73. Ernst T, Chang L, Leonido-Yec M, Speck O(2000) Evidence for long term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurol 54:1344–1349CrossRefGoogle Scholar
  74. Farre M, de la Torre, Llorente M, Lamas X, Ugena B, Segura J, Cami J (1993) Alkohol and cocaine into actions in humans. J Pharmacol Exp Ther 266:1364–1373Google Scholar
  75. Farre M, De La Torre R, Gonzalez ML et al (1997) Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther 283:164–176Google Scholar
  76. Felgate HE, Felgate PD, James RA, Sima DN, Vozzo DC (1998) Recent paramethoxyamphetamine deaths. J Analyt Toxicol 22:169–172CrossRefGoogle Scholar
  77. Feldmaier H (1997) Hilft ein Impfstoff gegen Cocainsucht? DAZ 137:2704–2705Google Scholar
  78. Fisch F, Wilson DC (1969) Excretion of cocaine and its metabolits in man. J Pharm Pharmacol 21:135SGoogle Scholar
  79. Fleurentin J, Pelt JM (1982) Repertory of drugs and medical plants of Yemen. J Etnopharmacol 6:85–108CrossRefGoogle Scholar
  80. Fodor G (1965) New methods and recent developments of ephedrine, pyrrolizidine, granatane and tropan alkaloids. Recent Dev Chem Nat Carbon Compd 1:15–20Google Scholar
  81. Freisleder A, Bautz W, Schmidt V (1988) Body Packing. Wertigkeit moderner bildgebender Verfahren zum Nachweis inkorporierter Transportmedien. Arch Kriminol 182:143–153Google Scholar
  82. Freyer E (1997) Kokain, Ecstasy und verwandte Designerdrogen.Wirkungsweise, Überdosierung, Therapeutische Notfallmaßnahmen. Johann Ambrosius Barth, Heidelberg LeipzigGoogle Scholar
  83. Galambos E, Pfeifer AK, György L, Molnár D (1967) Study of the excitation induced by amphetamine, cocaine and alpha-methyltryptamine. Psychopharmacol 11:122–129CrossRefGoogle Scholar
  84. Gawin FH (1991) Cocaine addiction: Psychology and Neurophysiol. Sci 251:1580–1586CrossRefGoogle Scholar
  85. Gay GR (1982) Clinical management of acute and chronic cocaine poisoning. Am Emerg Med 11:562–572CrossRefGoogle Scholar
  86. Gay GR, Sheppard CW, Inaba DS, Newmeyer JA (1973a) Cocaine in perspective: „Gift from the Sun God“ to „The Rich Man’s Drug“. Drug Forum 2:409–430Google Scholar
  87. Gay GR, Sheppard CW, Inaba DS, Newmeyer JA (1973b) An old girl: Flyin’ slow, dyin’ slow, blindes by snow: Cocaine in perspective. Int J Addict 8:1027–1042CrossRefGoogle Scholar
  88. Giannini AJ, Miller NS, Turner CE (1992) Treatment of khat addiction. J Sub Abuse Treatm 9(4):379–382CrossRefGoogle Scholar
  89. Gibbons S, Zioh M (2010) An analysis of the “legal high” mephedrone. Bioorgan & Medicin Chem Let 20(14):4135–4139CrossRefGoogle Scholar
  90. Glennon RA, Ismaiel AEM, Martin B, Poff D, Sutton M (1988) A preliminary behavioral investigation of PMMA the 4-methoxy analog of methamphetamine. Pharmacol Biochem and Behavior 31(1):9–13CrossRefGoogle Scholar
  91. Goeders NE, Smith JE (1983) Cortical dopaminergic involvement in cocaine reinforcement. Sci 221:773–775CrossRefGoogle Scholar
  92. Gorodetzky CW (1970) Marihuana, LSD, Amphetamines. Drug Depend 5:61–66Google Scholar
  93. Grabowsky J (hrsg) (1984) Cocaine: Pharmacology, effects and treatment of abuse. NIDA Res Monogr Rockville/MDGoogle Scholar
  94. Grasshof H(1962) Zusammenhänge zwischenKonstitution und Wirksamkeit bei Lokalanästhetica. Fortschr Arzneimittelforsch 4:353–357Google Scholar
  95. Grinspoon L, Bakalar JB (1976) Cocaine: A drug and its social evolution. Basic Books, New YorkGoogle Scholar
  96. Grinspoon L, Bakalar JB (1977) A kick from cocaine. A review of research on the drug‘s effects physical, social, and psychosocial. Psychol Today 3(78):41–42Google Scholar
  97. Gundlach H, Metraux (1979) Freund, Kokain, Koller und Schleich. Psyche 33:434–451Google Scholar
  98. Gustavsson D, Escher C (2009) Mephedrone – internet drug with seems to have come and stay. Fatal cases in Sweden which have drawn attention to previously unknown substances. Läkartidningen 106(43):2769–2771Google Scholar
  99. Halbach H (1981) Amphetamine. Dtsch Ärztebl 78(50):2398–2402Google Scholar
  100. Halikas JA, Crosby RD, PearsonVLet al (1997)Arandomized double-blind study of carbamazepine in the treatment of cocaine abuse. Clin Pharmacol Ther 62:89–105CrossRefGoogle Scholar
  101. Hanna JM (1974) Coca leaf use in southern Peru: Some biosocial aspects. Am Anthropol 76:281–296CrossRefGoogle Scholar
  102. Hanna JM, Hornick CA (1977) Use of coca leaf in southern Peru: adoption or addiction. Bull Narc 29:63–74Google Scholar
  103. Harkey MR, Henderson GL, Zhou C (1991) Simultaneous Quantitation of Cocain and it’s Major Metabolits in Human Hair by Gaschromatography/Chemical Ionisation Mass Spectrometry. J Anal Toxicol 15:260–264CrossRefGoogle Scholar
  104. Hasse HE, Schönhofer PS, Waldmann H (1973) Die Bedeutung weckaminartiger Substanzen in der Psychodynamik des Drogenkonsums bei Jugendlichen. Dtsch MedWochenschr 98:295–301CrossRefGoogle Scholar
  105. Hearn WL, Rose S, Wagner J et al (1991) Cocaethylene is more potent than cocaine in mediating lethality. Pharmacol Biochem Behav 39:531–533CrossRefGoogle Scholar
  106. Heinemann A, Lockermann U, Iwersen S, Püschel K, Schmoldt A (1997) Cocain – Nur eine Modedroge?. Kriminalistik 8(9):591–595Google Scholar
  107. Heinemann A, Miyaishi S, Iwersen S et al (1998) Bodypacking as cause of unexpected sudden death. J Forensic Sci 92:1–10Google Scholar
  108. Hirsch C (1982) Die Stellung des Kokains in der Lokalanästhesie einst und jetzt. Schmerz 1:105–113Google Scholar
  109. Hößelbarth S (2014) Crack, Freebase, Stein. Konsumverhalten und Kontrollstrategien von KonsumentInnen rauchbaren Kokains. Springer, WiesbadenGoogle Scholar
  110. Hoffman R, Al’absi M (2010) Khat use and neurobehavioural functions: suggestions for future studies. J Ethnopharmalcol 132(3):554–563CrossRefGoogle Scholar
  111. Hoffmann K-D (1998) Kokain – „Schnee“ aus den Anden. Kriminalistik 11:702–705Google Scholar
  112. Hoffmann K-D (2008) Der „Drogenkrieg“ in Mexiko –Auge um Auge, Zahn um Zahn. Kriminalistik 8(9):493–499Google Scholar
  113. Hollister LE, Gillespie HK (1970) Marihuana, ethanol and dextroamphetamine – mood and mental function alteration. Arch Clin Psychiatry 23:199–204CrossRefGoogle Scholar
  114. Holmann RB (1994) Biological effects of central nervous system stimulants. Addict 89:1435–1441CrossRefGoogle Scholar
  115. Iffland R (1982) Fenetyllin- und Amphetaminspiegel im Urin nach Einnahme von Captagon. Arch Kriminol 169:81–88Google Scholar
  116. Isenschmid DS, Fischman MW, Foltin RW, Caplan YH (1992) Concentration of cocaine and metabolits in plasma of humans following intravenous administration and smoking of cocaine. J Anal Toxocol 16:311–314CrossRefGoogle Scholar
  117. Isenschmid DS, Levine BS, Caplan YH(1992) The role of ecgonine methyl ester in the interpretation of cocaine concentrations in postmortem blood. J Anal Toxicol 16:319–324CrossRefGoogle Scholar
  118. Isner JM, Chokski SK (1991) Cardiovascular complications of cocaine. Curr Probl Cardiol 45: 93–121Google Scholar
  119. Iversen L (2006) Speed, Ecstasy, Ritalin: the Science of Amphetamines. Oxford University Press, OxfordGoogle Scholar
  120. Iyo M, Nishio M, Itoh T et al (1993) Dopamine D2 and Serotonine S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography. Psychiatry Research 50:217–231CrossRefGoogle Scholar
  121. Jain NC, Chinn DM, Sneath TC, Budd RD (1977) Simultaneous gas chromatographic determination of cocaine, methadone, methaqualone, phencyclidine, and propoxyphene. J Anal Toxicol 1: 192–194CrossRefGoogle Scholar
  122. Jatlow P (1993) Cocaethylene: pharmacologic activity and clinical significance. Ther Drug Monit 15:533–536CrossRefGoogle Scholar
  123. Javaid JL, Dekirmenjan H, Davis JM, Schuster CR (1978) Determination of cocaine in human urine, plasma and red blood cells by gasliquid chromatography. J Chromatogr 152:105–113CrossRefGoogle Scholar
  124. Javaid JL, Fischman MW, Schuster CR et al (1978) Cocaine plasma concentration: Relation to physiological and subjective effects in humans. Sci 202:227–228CrossRefGoogle Scholar
  125. Jeri FR (1979) Further experience with the syndromes produced by coca paste. Bull Narc 15:1–8Google Scholar
  126. Jeri FR, Sanchez CC, Del Pozo T, Fernandez M (1978a) The syndrome of coca paste. J Psychedelic Drugs 10:361–370CrossRefGoogle Scholar
  127. Jeri FR, Sanchez CC, Del Pozo T, Fernandez M (1978b) Further experience with the syndromes produced by coca paste smoking. Bull Narc 30:1–11Google Scholar
  128. Jindal SP, Lutz T, Vestergaard P (1978) Mass spectrometic determination of cocaine and its biologically active metabolite, norcocaine, in human urine. Biomed Mass Spectrom 5:658–663CrossRefGoogle Scholar
  129. Joachim H, Hochreuther J (1977) Untersuchungen über den Kombinationseffekt von Alkohol –Fenetyllin (Captagon) auf einige Reflexmechanismen des Menschen. Blutalkohol 14:25–46Google Scholar
  130. John H, Schoenberger R, Renner N, Ritz R (1992) Cocain-Intoxikation durch Drogentransport im Gastrointestinaltrakt (Body-Packer-Syndrom). Dtsch MedWochenschr 117(51–52):1952–1955Google Scholar
  131. Jordan SE, Lasslo A, Livingston HL, Alperin H (1958) Comparative pharmacology of cocaine and the diethylamide derivate of cocaine. Arch Int Pharmacodyn 4:452–473Google Scholar
  132. Kalix P (1988) Khat – ein pflanzliches Amphetamin. Dtsch Apoth Z 128:2150–2153Google Scholar
  133. Kalix P (1992) Cathinone, a Natural Amphetamine. Pharmacol Toxicol 70:77–82CrossRefGoogle Scholar
  134. Kalix P (1994) Khat, an amphetamine-like stimulant. J Psychoaktive Drugs 26:69–74CrossRefGoogle Scholar
  135. Kalix P, Brenneisen R, Koelbing U et al (1991) Khat, eine pflanzliche Droge mit Amphetaminwirkungen. Schweiz MedWochenschr 121:1561–1466Google Scholar
  136. Kalus F,Kucher J, Zutt J (1950) Über die psychotischen Bilder bei chronischem Pervitinmissbrauch. Psychiatr Neurol Med Psychol 2: 109–116, 138–144Google Scholar
  137. Karch SB, Billingham BE (1988) The pathology and etiology of cocaineinduced heart disease. Arch Pathol Lab Med 112:225–230Google Scholar
  138. Karch SB, Stephens BG, Ho C (1999) Methamphetamine-related deaths in San Francisco: demographic, pathologic and toxicologic profiles. J Forensic Sci 44:359–368CrossRefGoogle Scholar
  139. Katzung W (1991) Drogen: Information in Übersichten V. Abhängigkeit vom Cocain-Typ –Leitdroge Cocain. Medizin aktuell 17:400–403Google Scholar
  140. Kauert G, Röhrich J, Schmidt K (1995) Bestimmung von Amphetamin. Toxichem Krimtech 62: 14–20Google Scholar
  141. Kellner E (1960) Preludinsucht und Preludinpsychose. Ther GGW 99: 524–530Google Scholar
  142. Kelly JP (2011) Cathinone derivates: A review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis 3:439–453CrossRefGoogle Scholar
  143. Keup W (1990) Kokainmissbrauch in der Bundesrepublik Deutschland. BKA Forschungsreihe, Bundeskriminalamt WiesbadenGoogle Scholar
  144. Kilbey MM, Breslau N, Audreski P (1992) Cocaine use and dependence in young adults: associated psychiatric disorders and personality traits. Drug Alcohol Depend 29:283–290CrossRefGoogle Scholar
  145. Klinger S, Grapp M, Desel H, Grellner W (2015) Zur aktuellen Entwicklung des Methamphetaminkonsums in der Mitte Deutschlands – rechtsmedizinische Aspekte. BA 52:61–71Google Scholar
  146. Knecht T (2002) Methamphetamin – Gefährlicher Inhaltsstoff der „Thai-Pille“. Kriminalistik 6:402–405Google Scholar
  147. Kogan MJ, Vereby kg, Depace AC et al (1977) Quantitative determination of benzoylecgonine and cocaine in human biofluids by gasliquid chromatography. Anal Chem 49:1965–1969CrossRefGoogle Scholar
  148. Körner HH (1989) Doping: Der Drogenmissbrauch im Sport und Stall. ZRP 11:418–422Google Scholar
  149. Körner HH (2003) Wo viel Licht ist, ist auch Schatten. Ein Beitrag zur Glaubwürdigkeit der Dopingbekämpfung. Kriminalistik 1:49–54Google Scholar
  150. Kosten TR, Kleber HD, Morgan C (1989) Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 44:887–892CrossRefGoogle Scholar
  151. Kosten TR, Silverman DG, Fleming J et al (1992) Intravenous Cocaine challenges during naltrexone maintenance: a preliminary study. Biol Psychiatr 32:543–548CrossRefGoogle Scholar
  152. Kowalewski H (1990) Body-Packer-Syndrom. Rauschgiftschmuggel im menschlichen Körper –Diskussion aus juristischer und medizinischer Sicht an Hand eigener Fälle. Fortschr Med 108(24):467–469Google Scholar
  153. Kozel, Adams (hrsg) (1985) Cocaine Use in America. NIDA Res Monogr Series 61, Rockville/MD Kramer E (1941) Die Pervitingefahr. MMW 16:419–427Google Scholar
  154. Krause K-H, Krause J, Trott G-H (1998) Das hyperkinetische Syndrom (Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen) des Erwachsenenalters. Nervenarzt 69(7):543–556CrossRefGoogle Scholar
  155. Kuhn KL, Halikas JA, Kemp KD (1989) Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr 95:316–317Google Scholar
  156. Ladewig D, Battegay R, Labhardt F (1969) Stimulantiensucht und -psychosen. Dtsch Med Wochenschr 94:101–107CrossRefGoogle Scholar
  157. Lange RA et al (1989) Cocaine induced coronary artery vasoconstriction. N Eng J Med 321: 1557–1562CrossRefGoogle Scholar
  158. Laudry MJ (1992) An overview of cocaethylene, an alcohol-derived, psychoactive, cocaine metabolite. J Psychoactive Drugs 24:273–276CrossRefGoogle Scholar
  159. Lemmer B (1982) Benzodiazepine undAppetitzügler – Gebrauch und Missbrauch. Med Monatsschr Pharm 4:225–233Google Scholar
  160. Linck J (1987) Doping und staatliches Recht. NJW 41:2545–2548Google Scholar
  161. Logan BK (1996) Methamphetamine and driving impairment. J Forensic Sci 41:456–464Google Scholar
  162. Logan BK, Peterson KL (1994) The origin and significance of ecgonine methyl ester in blood sampl. J Anal Toxicol 18:124–125CrossRefGoogle Scholar
  163. Logan BK, Fligner C, Haddix T (1998) Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 43:28–34Google Scholar
  164. Lundberg GD, Garriott JC, Reynolds PC, Cravey RH (1977) Cocaine-related death. J Forsensic Sci 22:402–408Google Scholar
  165. Marc B, Brand FJ, Aelion MJ et al (1990) The cocaine body-packer Syndrome: evaluation of a method of contrast study of the bowel. J Forensic Sci 35(2):345–355CrossRefGoogle Scholar
  166. Martin RT (1970) The role of coca in the history, religion, and medicine of South American Indians. Econ Bot 24(4):422–438CrossRefGoogle Scholar
  167. Marzute PM, Tardiff K, Smyth D et al (1992) Cocaine Use, Risk Taking and Fatal Russian Roulette. JAMA 267(19):2635–2637CrossRefGoogle Scholar
  168. McCance-Katz EF, Price LH, McDougle CJ, Kosten TR, Black JE, Jatlow PI (1993) Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behaviour, and the role of cocaethylene. Psychopharmacolog (Berl) 111:39–46CrossRefGoogle Scholar
  169. Meashan F, Moore K, Newcombe R, Welch Z (2010) Tweaking, bombing, dabbing and stockpilling: The emergence of mephedrone and the perversity of prohibition. Drugs and Alcohol Today 10:14–21CrossRefGoogle Scholar
  170. Megges G (1983) Massive psychische Abhängigkeit …, Cocain – Cocaismus, Cocainismus. Kriminalistik 2:62–69Google Scholar
  171. Megges G (1986) „Speed“ – Zur Suchtgefährlichkeit der Amphetamine. Kriminalistik 5:224Google Scholar
  172. Meltzer PC, Butler D, Deschamps JR, Madras BK (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-ylpentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Medic Chem 49:1420–1432CrossRefGoogle Scholar
  173. Mendelson J, Jones RT, Upton R, Jacob III P (1995) Methamphetamine and alcohol interactions in humans. Clin Pharmacol Ther 57:559–568CrossRefGoogle Scholar
  174. Meyer MR, Wilhelm J, Peters FT, Mauerer HH (2010) Beta-keto amphetamines: Studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Analyt Bioanalyt Chem 397(3):1225–1233CrossRefGoogle Scholar
  175. Minister für Arbeit, Gesundheit und Soziales des Landes NordrheinWestfalen (Hrsg) (1981) Cocain heute. Dokumentation des IDIS.Verlag für Dokumentation und Information über Sozialmedizin und öffentliches Gesundheitswesen, BielefeldGoogle Scholar
  176. Mittleman RE, Wetly CV (1987) Cocaine and Sudden „Natural“ Death. J Forensic Sci 32(1):11–19CrossRefGoogle Scholar
  177. Mittleman RE, Wetly CV (1991) The pathology of cocaine abuse. Advances in pathology and laboratory medicine. Mosby-Year Book, Inc, Saint Louis, S. 37–73Google Scholar
  178. Möller MR, Bregel D, Hartung M, Warth S (1995) Quantitative Bestimmung von Cocain und Benzoylcocain aus Serum mittels Festphasenextraktion. Toxichem Krimtech 62:28–30Google Scholar
  179. Morrish PK, Nicolaou N, Brakkenberg P, Smith PE (1999) Leukoencephalopathy associated with khat misuse. J Neurol, Neurosurg and Psychiatry 67(4): 556CrossRefGoogle Scholar
  180. Mortimer WG (1974) History of coca. „The divine plant“ of the Incas. And/Or Press, San FranciscoGoogle Scholar
  181. Mule SJ (Hrsg) (1976) Cocaine. Chemical, biological, clinical, social and treatment aspects. CRC Press, Cleveland/OHGoogle Scholar
  182. Murphy HBM, Rios O, Negrete JC (1969) The effects of abstinence and of retraining an the chewer of coca leaf. Bull Narc 21:41–47Google Scholar
  183. Mußhoff F, Wollersen H, Madea B (2007) Über die Beeinträchtigung der Fahrsicherheit nach Konsum von Amphetaminen. BA 49:51Google Scholar
  184. Mußhoff F, Madea B (2012) Driving under the influence of amphetamine-like drugs. J Forensic Sci 57:413–419CrossRefGoogle Scholar
  185. Nagai F, Nonaka R, Kamimura KHS (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Europ J Pharmacol 559(2-3):132–137CrossRefGoogle Scholar
  186. Nichols GR, Davis GJ (1992) Body packing with a twist – death of a sales man. Am J Forens Med Pathol 13:142–145CrossRefGoogle Scholar
  187. Niedbala RS, Kardos K, Fries T, Cannon A, Davis A (2001) Immunoassay for Detection of Cocaine/Metabolites in Oral Fluids. J Anal Toxicol 25:62–68CrossRefGoogle Scholar
  188. Nieforth KS (1971) Psychotomimetic phenethylamine. J Pharm Sci 60:655–659CrossRefGoogle Scholar
  189. Nieschulz O (1969) Kokaismus und Kokainismus. MMW 44:2276–2284Google Scholar
  190. Nieschulz O (1971) Psychopharmakologische Untersuchungen über Cocain und Ecgonin. Ein Beitrag zum Problem des Cocaismus und Cocainismus. Arzneimittelforsch 21:275–284Google Scholar
  191. Nieschulz O, Schmersahl P (1969) Untersuchungen über die Bedeutung des Kalkzusatzes beim Kauen von Coca-Blättern. Planta Med 17:178–183CrossRefGoogle Scholar
  192. Nobel H (1985) Teufelsdroge Nr. 2 auf dem Vormarsch – Kokain: Schmuggel, Preise, Anwendungsformen. Kriminalistik 3:130–149Google Scholar
  193. Nossoll M, Teuchert-Noodt G, Dawirs RR (1997) A single dosis of methamphetamine in neonatal gerbils affects adult prefrontal GABA innervation. Eur J Pharmacol 340:3–5Google Scholar
  194. Odenwald M (2007) Chronic khat use and psychotic disorders: a review oft he literature and future prospects. Sucht 53:9–22CrossRefGoogle Scholar
  195. Oglakioglu MT, Henne-Bruns D, Wittau M (2011) Unerlaubte Einfuhr von Betäubungsmitteln durch „Bodypacking“ – Rechtliche und miedizinische Grundlagen. NStZ 2:73–76Google Scholar
  196. Pallenbach E (1996) Die Männer mit der dicken Backe. Khat im Jemen. DtschApothek Z 136:3399–3410Google Scholar
  197. Panse F, Klages W (1964) Klinisch-psychopathologische Beobachtungen bei chronischem Missbrauch von Ephedrin und verwandten Substanzen. Arch Psychiatr Nervenkr 206:69–95CrossRefGoogle Scholar
  198. Philipps J, Wynne RD (1980) Cocaine. Avon, New YorkGoogle Scholar
  199. Pickering H, Stimson GV (1994) Prevalence and demographic factors of stimulant use. Addict 89:1385–1389CrossRefGoogle Scholar
  200. Post RM (1975) Cocaine psychosis: A continuum model. Am J Psychiatry 132:225–231CrossRefGoogle Scholar
  201. Post RM, Kotin J, Goodwin FK (1974) The effects of cocaine on depressed patients.AmJ Psychiatry 131:511–517CrossRefGoogle Scholar
  202. Post RM, Kopanda RT (1976) Cocaine, kindling, and psychosis. Am J Psychiatry 133:627–634CrossRefGoogle Scholar
  203. Prokop H (1968) Halluzinose bei Ephedrinsucht. Nervenarzt 39:71–75Google Scholar
  204. Prokop H (1969) Über Fälle mit Ephedrin- und Preludinsucht.Wien KlinWochenschr 81:269–271Google Scholar
  205. Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Medical Toxicol 8(1):33–42CrossRefGoogle Scholar
  206. Püschel K, Schulz F, Iwersen S, Schmoldt A (1995) Tod nach Verschlucken von Rauschgift. Kriminalistik 5:355–358Google Scholar
  207. Rafla FK, Epstein RL (1979) Identification of cocaine and its metabolits in human urine in the presence of ethyl alcohol. J Anal Toxicol 3:59–63CrossRefGoogle Scholar
  208. Reinarman C, Levine HG (1997) Crack in America – Demon Drugs an Social Justice, University of California, Berkeley Press and Los AngelesGoogle Scholar
  209. Resnick RB, Kestenbaum RS, Schwarz LK (1976) Acute systemic effects of cocaine in man: A controlled study by intranasal and intravenous routes. Psychopharmacol Bull 12:44–45Google Scholar
  210. Rezkalla SH, Hale S, Kloner RA (1990) Cocaine induced heart diseases. Am Heart J 120(6):1403–1408CrossRefGoogle Scholar
  211. Ritz MG, Kuhar MJ (1989) Relationship between a self administration of amphetamine and monoamine receptors: comparison with cocaine. J Pharmacol Exp Ther 248:1010–1017Google Scholar
  212. Röhrich J, Schmidt K, Bratzke H (1995) Nachweis von Amphetamin-Derivaten bei chemischtoxikologischen Untersuchungen über den Zeitraum 1987–1993 im Großraum Frankfurt. Blutalkohol 32:42–29Google Scholar
  213. Sahihi A (1990) Designer-Drogen: Crack, die effektvollste aller Zerstörungen. Suchtreport 4(6): 42–47Google Scholar
  214. Salchert O (2014) Methamphetamin (Crystal) in Sachsen. Kriminalistik 10:563–571Google Scholar
  215. Sano J, Nagasaka (1956) Über chronische Weckaminsucht in Japan. Fortschr Neurol Psychiatr 24:291–394Google Scholar
  216. Sauer W, Freislederer A, Graw W, Schmidt V (1988) Sonografie bei intrakorporalem Drogenschmuggel. Dtsch Med Wochenschr 114:1855–1858Google Scholar
  217. Schechter MD (1990) Dopaminergic nature of acute cathine tolerance. Pharmacol Biochem Behavior 36(4):817–820CrossRefGoogle Scholar
  218. Vom Scheidt J (1973) Sigmund Freud und das Kokain. Psyche 27:385–430Google Scholar
  219. Schepers RJF, Oyler JM, Joseph RE, Cone EJ et al. (2003) Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 49:121–132CrossRefGoogle Scholar
  220. Shima N, Katagi M, Tsuchihashi H (2009) Direct analysis of conjugate metabolites of methamphetamine, 3,4-methylenedioxymethamphetamine, and their designer drugs in biological fluids. J Health Sci 55(4):495–502CrossRefGoogle Scholar
  221. Shimizu E, Watanabe H, Kojima T et al. (2007) Combined intoxication with methylone and 5-MeO-MIPT. Progres Neuro-Psychopharmacol Biol Psychiatry 31(1):288–291CrossRefGoogle Scholar
  222. Shimosato K, Gaa H, Tomita M, Doi Y (1998) Biphasic effects of alcohol drinking on methamphetamine metabolism in man. Alcohol and Alcoholism 23:351–357CrossRefGoogle Scholar
  223. Shulgin AT, Shulgin A (1995) PIKHAL: A chemical love story. Transform Press, BerkeleyGoogle Scholar
  224. Siegel RK (1978) Cocaine hallucinations. Am J Psychiatry 135:309–314CrossRefGoogle Scholar
  225. Singh S (2000) Chemistry, design and structure-activity relationship of cocaine antagonists. Chem Rev 100:925–1024CrossRefGoogle Scholar
  226. Skopp G, Daldrup T (2012) Konsum von Amphetamin und seiner Derivate. Pharmakokinetische Grundlagen und Nachweisbarkeitsdauer unter besonderr Berücksichtigung des § 24a (2) StVG. Blutalkohol 49:187–202Google Scholar
  227. Smith DE, Wasson DR (1978) Cocaine. J Psychedelic Drugs 10:351–360CrossRefGoogle Scholar
  228. Spiehler VR, Reed D (1985) Brain concentrations of cocaine and benzoylecgonine in fatal case. J Forensic Sci 40(4):1003–1011Google Scholar
  229. Stewart DJ, Inaba T, Lucassen M, Kalow W (1979) Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther 25:464–358CrossRefGoogle Scholar
  230. Stöver H, Prinzleve M (Hersg.) (2004) Kokain und Crack, Pharmakodynamiken, Verbreitung und Hilfsangebote. Lambertus-Verlag, FreiburgGoogle Scholar
  231. String DL, Hunt DE, Goldsmith DS (1985) Patterns of cocaine use among methadone clients. Int J Addict 20:1163–1175CrossRefGoogle Scholar
  232. Suarez CA, Arango A, Lester JL (1977) Cocaine – condom ingestion. Surg treat JAMA 238: 1391–1392Google Scholar
  233. Suzuki O, Hattori H, Asano M (1984) Nails and hair as useful materials for detection of methamphetamin or amphetamin abuse. Forensic Sci Intern 24:9–16CrossRefGoogle Scholar
  234. Szendrer K (1980) The chemistry of khat. Bill Narcotics 32(3):5–35Google Scholar
  235. Täschner K-L (1988) Koka und Kokain – Konsum undWirkungen. Deutscher Ärzteverlag, KölnGoogle Scholar
  236. Täschner K-L (1989) Cocain – Kein „Schnee“ von gestern. Dtsch Apoth Z 37:1955–1959Google Scholar
  237. Täschner K-L, Richtberg W (1982) Kokain-Report. Akademische Verlagsgesellschaft.WiesbadenGoogle Scholar
  238. Täschner K-L, Bort G (1987) Kokainmissbrauch – eine unterschätzte Gefahr?. Suchtgefahren 33:369–375Google Scholar
  239. Thamm BG (1984) Kokain – Schnee von Morgen. Psychol heute 11:56–59Google Scholar
  240. Thamm BG (1986) Andenschnee: die lange Linie des Kokains. Sphinx, BaselGoogle Scholar
  241. Toennes SW, Kauert GF (2000) Nachweis und Häufigkeit des kombinierten Konsums von Kokain und Ethanol. BA 37(6):434–439Google Scholar
  242. Toennes SW, Kauert GF (2004) Driving under the influence of khat: alkaloid concentrations and observations in forensic cases. For Sci Int 140(1):85–90Google Scholar
  243. Toennes SW, Iwersen-Bergmann S, Kauert GF (2007) Zur Bewertung analytischer Befunde in Blutproben von Kokainkonsumenten. BA 44(1):1–8Google Scholar
  244. Torrance H, Cooper G (2010) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Intern 202(1–3)CrossRefGoogle Scholar
  245. United Nations Office on Drugs and Crime (2012) Patterns and trends of amphetamine-type stimulants and other druigs, Asia and the Pacific. BangkokGoogle Scholar
  246. Vasiliades J (1993) Long-term stability of ecgonine methyl ester in urine. J Anal Toxicol 17:253CrossRefGoogle Scholar
  247. Villinger W (1941) Pervitin, Suchtproblem und Suchtbekämpfung. Nervenarzt 14:405–408Google Scholar
  248. Voigt HP (1982) Zum Thema: Kokain. Sphinx, BaselGoogle Scholar
  249. Weir S (1985) Qāt im Yemen. British Museum Publications, DorsetGoogle Scholar
  250. Westphal F, Junge T, Rösner P et al. (2006) Mass spectral and NMR spectral data oft wo new designer drugs with an α-aminophenone structure: 4’-methyl-α-pyrrolidinohexanophone and 4’-methyl-α-pyrrolidinobutyrophenone. For Sci Intern 169(1):32–42Google Scholar
  251. Westphal F, Junge T, Rösner P, Sönnichsen F, Schuster F (2009) Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: A designer drug with α-pyrrolidinophenone structure. For Sci Intern 190(1):1–3Google Scholar
  252. Wetli CV, Wright RK (1969) Death caused by recreational cocaine use. JAMA 241:2519–2522CrossRefGoogle Scholar
  253. Widler O, Mathys K, Brenneisen R et al (1994) Pharmacodynamics and pharmacokinetics auf khat: a controlled study. Clin Pharmacol Ter 55(5):556–562CrossRefGoogle Scholar
  254. Wikström M, Thelander G, Nyström I, Kronstrand R (2010) Two fatal intoxications with the new designer drug methedrone (4-Methoxymethcathinone). J Analyt Toxicol 34:594–598CrossRefGoogle Scholar
  255. Wilkinson P, Van Dyke C, Jatlow P et al (1980) Intranasal and oral cocaine kinetics. Clin Pharmacol Ther 27:386–394CrossRefGoogle Scholar
  256. Witkop B, Foltz CM (1957) Studies on the stereochemistry of ephedrine and ψ-ephedrine. J Chem Soc 79:197199Google Scholar
  257. Wood DM, Davies S, Puchnarewicz M et al. (2010) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol, 1 AprilGoogle Scholar
  258. Yui K, Goto K, Ikemoto S, Ishiguro T, Kamata Y (2000) Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity. J Clin Psychopharmacolog 20:165–174CrossRefGoogle Scholar
  259. Zaitsu K, Katagi M, Kamata H et al. (2009) Determination oft he metabolites oft he new disgner drugs bk-MBDB and bk-MDEA in human urine. For Sci Intern 188(1-3):131–139Google Scholar
  260. Zapata-Ortiz V, De La Mata R Castro, Barrantes Campos R (1961) Die anticonvulsiveWirkung des Cocains. Arzneimittelforsch 11:657–662Google Scholar
  261. Zimmermann P (1995) Drogenschmuggel imKörper: Erkenntnisse zu Methoden und zur Diagnostik des Körperschmuggels. Kriminalistik 8–9:556–559Google Scholar
  262. Zuckermann B, Frank DA, Hingson R et al (1989) Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 320:762–768CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Thomas Geschwinde
    • 1
  1. 1.HanauDeutschland

Personalised recommendations